People · Operator
Named in public records as an officer, director or promoter · active 2012–2014 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| eXIthera Pharmaceuticals, Inc. | — | Biotechnology | Series A | $15.0M | $108.5M | 2012 |
Frans Stassen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Frans Stassen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Daniel Behr | 1 | 4 |
| Ben Bronstein | 1 | 4 |
| William Koster | 1 | 3 |
| Scott J. Yaphe | 1 | 2 |
| Isaac Kohlberg | 1 | 2 |
| Dennis Goldberg | 1 | 1 |
| Frans J. Stassen | 1 | 1 |
| William J. Koster | 1 | 1 |
| Fred J. Meyer | 1 | 1 |
| Isaac J. Kohlberg | 1 | 1 |
| Neil J Hayward | 1 | 1 |
| Fred Meyer | 1 | 1 |
| Neil Hayward | 1 | 1 |
| Scott Yaphe | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.